Department of Clinical Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, China.
Endocr Metab Immune Disord Drug Targets. 2023;23(8):1051-1067. doi: 10.2174/1871530323666230127121738.
Diabetes mellitus (DM) is a metabolic disorder characterized by progressive β cell dysfunction. Sheng-Mai Injection (SMI), a Traditional Chinese medicine preparation, is widely used for DM and its related complications.
This meta-analysis aimed to summarize the applications of SMI in DM and related complications.
Eight databases were searched, and meta-analyses were performed.
Fifteen studies, including 1273 participants, were included. All studies and participants included were from China. Pooled effects showed that SMI might reduce glycated hemoglobin (MD -0.46%; 95% CI -0.89 to -0.03; P < 0.01), fasting blood glucose (MD -0.83 mmol/L; 95% CI -1.30 to -0.36; P < 0.01), two-hour postprandial glucose (MD -1.27 mmol/L; 95% CI -1.96 to -0.58; P < 0.01), 24-hour urinary protein (MD -0.28 mg; 95% CI -0.51 to -0.06; P = 0.01), blood urea nitrogen (MD -1.31 mg; 95% CI -2.08 to -0.54; P < 0.05), Scr (MD -2.60; 95% CI -3.43 to -1.77; P < 0.05), ulnar nerve motor nerve conduction velocity (MNCV) (MD 1.45; 95% CI 0.03 to 2.87; P < 0.05), and tibial nerve sensory nerve conduction velocity (SNCV) (MD 1.84; 95% CI 0.1 to 3.58; P < 0.05). There was no evidence of an effect on common peroneal nervous MNCV and SNCV, tibial nerve MNCV, median nerve MNCV, and SNCV. Adverse effects included less frequent gastrointestinal reactions, elevated transaminase, leucopenia, fever, and rash.
Combination use of SMI based on conventional hypoglycemic treatment can significantly improve HbA1c, FBG, and 2hPG in DM and reduce 24-hour urinary protein, Scr, and BUN in DM patients. SMI was found to have no effect on the neurological function of diabetic peripheral neuropathy.
糖尿病（DM）是一种以β细胞功能进行性衰退为特征的代谢性疾病。参麦注射液（SMI）是一种中药制剂，广泛用于治疗 DM 及其相关并发症。
本荟萃分析旨在总结 SMI 在 DM 及相关并发症中的应用。
检索了 8 个数据库，并进行了荟萃分析。
共纳入 15 项研究，包括 1273 名参与者。所有研究和参与者均来自中国。汇总效应表明，SMI 可能降低糖化血红蛋白（MD -0.46%；95%CI -0.89 至 -0.03；P < 0.01）、空腹血糖（MD -0.83 mmol/L；95%CI -1.30 至 -0.36；P < 0.01）、餐后 2 小时血糖（MD -1.27 mmol/L；95%CI -1.96 至 -0.58；P < 0.01）、24 小时尿蛋白（MD -0.28 mg；95%CI -0.51 至 -0.06；P = 0.01）、血尿素氮（MD -1.31 mg；95%CI -2.08 至 -0.54；P < 0.05）、Scr（MD -2.60；95%CI -3.43 至 -1.77；P < 0.05）、尺神经运动神经传导速度（MNCV）（MD 1.45；95%CI 0.03 至 2.87；P < 0.05）和胫神经感觉神经传导速度（SNCV）（MD 1.84；95%CI 0.1 至 3.58；P < 0.05）。但对腓总神经 MNCV 和 SNCV、胫神经 MNCV、正中神经 MNCV 和 SNCV 无影响。不良反应包括胃肠道反应发生率降低、转氨酶升高、白细胞减少、发热和皮疹。
在常规降糖治疗的基础上加用 SMI 可显著改善 DM 患者的 HbA1c、FBG 和 2hPG，并降低 DM 患者的 24 小时尿蛋白、Scr 和 BUN。SMI 对糖尿病周围神经病变的神经功能无影响。
